Limits...
De novo malignancy after liver transplantation: a single-center experience of 14 cases.

Gao PJ, Gao J, Li Z, Hu ZP, Zhu JY - Ann Surg Treat Res (2015)

Bottom Line: A total of 466 patients who had a minimum follow-up time of 6 months were enrolled in the study.The patients were all male.The types of de novo tumors included digestive system tumor (8 in 14), lung cancer (2 in 14), urologic neoplasm (2 in 14), and hematologic malignant tumor (2 in 14).

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China.

ABSTRACT

Purpose: The aim of this study is to evaluate the incidence of de novo malignancy after liver transplantation (LT) and compare with those among the general Chinese population.

Methods: A total of 466 patients who had a minimum follow-up time of 6 months were enrolled in the study. All data of medical records and follow up were retrospectively reviewed.

Results: The incidence rate of de novo malignancy was 3.0% (14 in 466 patients). The median elapsed time from transplant to the diagnosis of de novo malignancy was 42 months (range, 6 to 106 months). The cumulative risk for development of de novo malignancy was 1.6%, 2.7%, and 8.2% at 3, 5 and 10 years after LT, respectively. The patients were all male. The types of de novo tumors included digestive system tumor (8 in 14), lung cancer (2 in 14), urologic neoplasm (2 in 14), and hematologic malignant tumor (2 in 14). Over a mean follow-up of 24 months after diagnosis of de novo malignancy, 7 patients (50.0%) died; the overall 5-year patient survival rate was 54.5%. The relative risk of malignancy following LT was 9.5 folds higher than the general Chinese population.

Conclusion: The relative risk of malignancy following LT was much higher than the general Chinese population. Digestive system tumor is the most common type of de novo malignancy after LT in China.

No MeSH data available.


Related in: MedlinePlus

Clinical characteristics of the study population. LT, liver transplantation; HCC, hepatocellular carcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4384282&req=5

Figure 2: Clinical characteristics of the study population. LT, liver transplantation; HCC, hepatocellular carcinoma.

Mentions: There were 8 digestive system tumors, 2 lung cancers, 2 urologic neoplasms, and 2 hematologic malignant tumors (Fig. 2). Nine patients came to see the doctor for clinical symptoms. Five patients were diagnosed during periodic check-ups. These patients underwent aggressive treatment, including surgery, chemotherapy, and TACE (transhepatic arterial chemotherapy and embolization), except for one patient with an aggressive primary liver cancer. Each patient's details can be visualized in Table 3.


De novo malignancy after liver transplantation: a single-center experience of 14 cases.

Gao PJ, Gao J, Li Z, Hu ZP, Zhu JY - Ann Surg Treat Res (2015)

Clinical characteristics of the study population. LT, liver transplantation; HCC, hepatocellular carcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4384282&req=5

Figure 2: Clinical characteristics of the study population. LT, liver transplantation; HCC, hepatocellular carcinoma.
Mentions: There were 8 digestive system tumors, 2 lung cancers, 2 urologic neoplasms, and 2 hematologic malignant tumors (Fig. 2). Nine patients came to see the doctor for clinical symptoms. Five patients were diagnosed during periodic check-ups. These patients underwent aggressive treatment, including surgery, chemotherapy, and TACE (transhepatic arterial chemotherapy and embolization), except for one patient with an aggressive primary liver cancer. Each patient's details can be visualized in Table 3.

Bottom Line: A total of 466 patients who had a minimum follow-up time of 6 months were enrolled in the study.The patients were all male.The types of de novo tumors included digestive system tumor (8 in 14), lung cancer (2 in 14), urologic neoplasm (2 in 14), and hematologic malignant tumor (2 in 14).

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China.

ABSTRACT

Purpose: The aim of this study is to evaluate the incidence of de novo malignancy after liver transplantation (LT) and compare with those among the general Chinese population.

Methods: A total of 466 patients who had a minimum follow-up time of 6 months were enrolled in the study. All data of medical records and follow up were retrospectively reviewed.

Results: The incidence rate of de novo malignancy was 3.0% (14 in 466 patients). The median elapsed time from transplant to the diagnosis of de novo malignancy was 42 months (range, 6 to 106 months). The cumulative risk for development of de novo malignancy was 1.6%, 2.7%, and 8.2% at 3, 5 and 10 years after LT, respectively. The patients were all male. The types of de novo tumors included digestive system tumor (8 in 14), lung cancer (2 in 14), urologic neoplasm (2 in 14), and hematologic malignant tumor (2 in 14). Over a mean follow-up of 24 months after diagnosis of de novo malignancy, 7 patients (50.0%) died; the overall 5-year patient survival rate was 54.5%. The relative risk of malignancy following LT was 9.5 folds higher than the general Chinese population.

Conclusion: The relative risk of malignancy following LT was much higher than the general Chinese population. Digestive system tumor is the most common type of de novo malignancy after LT in China.

No MeSH data available.


Related in: MedlinePlus